Nothing Special   »   [go: up one dir, main page]

Williams et al. - Google Patents

New Curcuphenol Analogues Possess Anti-Metastatic Biological Activity

Williams et al.

View PDF
Document ID
7318168501217349950
Author
Williams D
Cheng P
Andersen R
Jefferies W

External Links

Snippet

For eons, turmeric and curcumin have been used as culinary spices and as traditional medicines and as vogue dietary supplements for a growing list of disorders, including arthritis, digestive disorders, respiratory infections, allergies, liver disease, depression and …
Continue reading at www.biorxiv.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Similar Documents

Publication Publication Date Title
Huber et al. Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Verbeke et al. Broadening the message: a nanovaccine co-loaded with messenger RNA and α-GalCer induces antitumor immunity through conventional and natural killer T cells
CN107921111B (en) Novel peptides, peptide compositions and scaffolds for immunotherapy of various cancers
Serafini Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly
CN108392633B (en) Application of PCSK9 inhibitor in malignant tumor immunotherapy
KR101164509B1 (en) Yeast-Based Vaccines as Immunotherapy
CN113480604A (en) Novel peptides and peptide compositions for immunotherapy of ovarian and other cancers
Luo et al. Lanthanide-nucleotide coordination nanoparticles for STING activation
UA126787C2 (en) PEPTIDE, NUCLEIC ACID, EXPRESSION VECTOR, HOST CELL, METHOD OF OBTAINING THE PEPTIDE, ACTIVATED CYTOTOXIC T-LYMPHOCYTES AND THEIR METHOD OF OBTAINING AND USING THEM, METHOD OF TREATMENT OF CANCER
JP4611022B2 (en) Cancer antigen peptide preparation
EP4005591A1 (en) Anti-neoplastic combined pharmaceutical composition and application thereof
EA029831B1 (en) Peptide inducing cytotoxic t lymphocytes and stimulating anti-tumor immune responses
Martin et al. Role of myeloid-derived suppressor cells in tumor immunotherapy
Lee et al. Interleukin-10 attenuates tumour growth by inhibiting interleukin-6/signal transducer and activator of transcription 3 signalling in myeloid-derived suppressor cells
US20210046156A1 (en) Altering inflammatory states of immune cells in vivo by modulating cellular activation states
EP3468585A2 (en) Calr and jak2 vaccine compositions
CN115135764A (en) Nanoparticle system for stimulating and maintaining immune system responsiveness at a treatment site
CN115925806A (en) Novel peptides, peptide compositions and scaffolds for immunotherapy of various cancers
Li et al. Liposomal co-delivery of PD-L1 siRNA/Anemoside B4 for enhanced combinational immunotherapeutic effect
Al Subeh et al. Lipid nanoparticle delivery of fas plasmid restores fas expression to suppress melanoma growth in vivo
Wang et al. Naringenin enhances the antitumor effect of therapeutic vaccines by promoting antigen cross-presentation
Dada et al. Specific cannabinoids revive adaptive immunity by reversing immune evasion mechanisms in metastatic tumours
Gao et al. Targeting neutrophils potentiates hitchhiking delivery of drugs and agonists for postsurgical chemo-immunotherapy
US11559504B2 (en) Ceramide nanoliposomes, compositions and methods of using for immunotherapy
Ellis et al. Complete Synthesis and Stereochemical Assignment of Novel Curcuphenol Analogues Possessing Anti-Metastatic Cancer Biological Activity